Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023
Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.
The cancer supportive care drugs market is segmented based on drug class, cancer type, and region. the cancer supportive care drugs by drug class include granulocyte-colony stimulating factors (g-csfs), erythropoietin-stimulating agents (esas), antiemetics, bisphosphonates, opioids, nonsteroidal anti-inflammatory drugs (nsaids), others.
North America is expected to dominate the market in 2018, with the US accounting for a major share. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period, due to the factors such as rising incidence of cancer, and expansions of major pharmaceutical companies in emerging Asian economies.
Table of Contents
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
6 Cancer Supportive Care Drugs Market, By Drug Class
6.1 Granulocyte-Colony Stimulating Factors (G-CSFS)
6.2 Erythropoietin-Stimulating Agents (ESAS)
6.3 Antiemetics
6.4 Bisphosphonates
6.5 Opioids
6.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
6.7 Other Drug Classes
7 Cancer Supportive Care Drugs Market, By Cancer Type
7.1 Breast Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Prostate Cancer
7.5 Other Cancers
8 Cancer Supportive Care Drugs Market, By Region
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.4 Asia Pacific
8.5 RoW
9 Competitive Landscape
9.1 Market Overview
9.2 Market Ranking Analysis, 2018
9.3 Competitive Situation and Trends
9.3.1 Product Launches & Approval
9.3.2 Acquisitions
9.3.3 Agreements
9.3.4 Other Developments
10 Company Profiles
(Business Overview, Recent Financials, Products Offered, Recent Developments, MnM View)*
10.1 Amgen
10.2 Johnson & Johnson
10.3 Novartis
10.4 Baxter International
10.5 Fagron Group.
10.6 Teva Pharmaceuticals Industries
10.7 Hoffmann La- Roche
10.8 Apr Applied Pharma Science Research
10.9 Acacia Pharma
10.10 Kyowa Hakko Kirin
*Details on Business Overview, Recent Financials, Recent Developments, Key Relationships Might Not Be Captured in Case of Unlisted Companies.
11 Appendix
Growth opportunities and latent adjacency in Cancer Supportive Care Drugs Market